Vyteris gets grant for smart patch; Cedars-Sinai targets brain tumors

> Vyteris has received a $489,000 grant under the U.S. Qualifying Therapeutic Discovery Project program. The money will be used to advance Vyteris' smart patch drug delivery technology for female infertility and diabetes. Vyteris release

> A Cedars-Sinai research team has created a "nanobioconjugate" drug that may be given by intravenous injection and carried in the blood to target brain tumors. It is engineered to specifically permeate the tumor cell wall, entering endosomes, mobile compartments within cells. Report

> Nuvo Research, which focuses on topical and transdermal drug delivery technologies, has announced that its Phase II clinical trials in Europe evaluating its drug WF10 as a treatment for severe allergic rhinitis has met its primary endpoint. The trial assessed the efficacy and safety of WF10 infusions for the treatment of patients with severe persistent allergic rhinitis. Nuvo release

> According to companiesandmarkets.com, Novartis leads the $5.6 billion transdermal drug delivery market. Item

> Drug delivery abstract of the week: Engineering Liposomes and Nanoparticles for Biological Targeting. Abstract

> Drug delivery patent application of the week: Nanocell drug delivery system. Patent application

> Drug delivery video of the week: Facilitating Drug Delivery to the Brain--Big Ideas 2010--Enterprise Ireland. Video

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.